Patent US2609320A successfully refreshed from Google Patents.
US5885982A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Use of transglutaminase inhibitor for the treatment of scar tissue
Assignee: University of Manitoba
•
Filing: 1992-03-23
•
Granted: 1999-03-23
•
Expires: 2012-03-23
Abstract
Abstract A method of treating or preventing hypertrophic scar tissue in human skin comprising applying topically an effective amount of a non-toxic amine compound that is a transglutaminase inhibitor having a free amino group is disclosed. The amine compound that is a transglutaminase inhibitor is also selective for inhibiting Type III collagen peptide cross-linking.
Inventors
- 👤 Kenneth Nicholis Dolynchuk
- 👤 John Michael Bowness
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 12:54
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/13; A61K31/135; A61K31/275; A61P; A61P17/00; A61P43/00
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
82 words
A method of treating or preventing hypertrophic scar tissue in humans, comprising applying to extracellular wound scar tissue in human skin an effective amount of a non-toxic amine compound having a free amino group, said amine compound being a transglutaminase inhibitor which is selective for inhibiting Type III collagen peptide cross-linking, or a pharmaceutically-acceptable acid addition salt of said amino compounds, in the form of a composition with a pharmaceutically-acceptable carrier or diluent and formulated for topical application to said extracellular wound.
Claim 2
Independent Claim
82 words
A method of treating or preventing hypertrophic scar tissue in humans, comprising applying to extracellular wound scar tissue in human skin an effective amount of a non-toxic amine compound having a free amino group, said amine compound being a transglutaminase inhibitor which is selective for inhibiting Type III collagen peptide cross-linking, or a pharmaceutically-acceptable acid addition salt of said amino compounds, in the form of a composition with a pharmaceutically-acceptable carrier or diluent and formulated for topical application to said extracellular wound.
Claim 3
Dependent Claim
15 words
A method according to claim 1, wherein the effective amount is 25 to 100 mM.
Claim 4
Dependent Claim
14 words
A method according to claim 2, wherein the effective amount is about 50 mM.
Claim 5
Dependent Claim
14 words
A method according to claim 1, wherein the amine compound is a primary amine.
Claim 6
Dependent Claim
12 words
A method according to claim 4, wherein the amine is a polyamine.
Claim 7
Dependent Claim
14 words
A method according to claim 5, wherein the amine is a C1-5 alkyl amine.
Claim 8
Dependent Claim
11 words
A method according to claim 6, wherein the amine is putrescine.
Claim 9
Dependent Claim
15 words
A method according to claim 7, wherein the carrier is a eutectic cream or ointment.
Claim 10
Dependent Claim
16 words
The method of claim 8 including the further step of occluding the wound with a dressing.
References Cited (Backward Citations)
US4226858A
Cited
US4618490A
Cited
US4444787A
Cited
US4428939A
Cited
US4507321A
Cited
US4485088A
Cited
US4929630A
Cited
US4694021A
Cited
US4946870A
Cited
US4970297A
Cited
US4968713A
Cited
US5132119A
Cited
US4997854A
Cited
WO1991010427A2
Cited
US5124358A
Cited
US5324508A
Cited
US5120322A
Cited
US5411940A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2002-03-22 | 2002-09-21 | 2003-03-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2006-03-22 | 2006-09-21 | 2007-03-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2010-03-22 | 2010-09-21 | 2011-03-23 | $7700.00 | Window Closed / Lapsed |